Use of, time to, and type of first add‐on anti‐hyperglycaemic therapy to metformin in Australia, 2018–2022
Amongst people initiating metformin from 2018 to 2020, there was an increasing proportion of SGLT2i and GLP-1 RA being used as first add-on therapy. However, the overall prevalence of add-on therapy was low. Advocacy to promote add-on therapy with cardiorenal beneficial medicines is critical to reduce type 2 diabetes morbidity and mortality.
Authors
- Jerry Richard Greenfield (ORCID: https://orcid.org/0000-0002-0866-0973)
- SOPHIE LENA STOCKER (ORCID: https://orcid.org/0000-0002-2114-587X)
- Tamara Y. Milder (ORCID: https://orcid.org/0009-0002-0538-2661)
- Brendon Lange Neuen (ORCID: https://orcid.org/0000-0001-9276-8380)
- Sallie‐Anne Pearson (ORCID: https://orcid.org/0000-0001-7137-6855)
- Jialing Lin (ORCID: https://orcid.org/0000-0002-0643-9191)
- Michael O. Falster (ORCID: https://orcid.org/0000-0001-6444-7272)
- Juliana de Oliveira Costa (ORCID: https://orcid.org/0000-0002-8355-023X)
- Richard Osborne Day (ORCID: https://orcid.org/0000-0002-6045-6937)
Institutions
- The University of Sydney (AU)
- Garvan Institute of Medical Research (AU)
- Royal North Shore Hospital (AU)
- UNSW Sydney (AU)
- St Vincent's Hospital Melbourne (AU)
- St Vincent's Hospital Sydney (AU)
- St Vincent's Health (AU)
- The George Institute for Global Health (AU)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1111/bcp.16231
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.07
Funders
- Australian Government
- National Heart Foundation of Australia
- University of New South Wales
- Medical Research Council
- National Health and Medical Research Council